Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment (NQF 0004)

Measure Basic Information

Name and date of specifications used: HEDIS® MY2020/2021, Volume 2 Technical Specifications for Health Plans.

URL of Specifications: N/A

- HEDIS
- PQI
- Survey
- Other Specify:

Measure Utility:

- CCO Incentive
- State Quality
- CMS Adult Core Set
- CMS Child Core Set
- Other Specify:

Data Source: MMIS/DSSURS


<table>
<thead>
<tr>
<th>Benchmark for OHA measurement year</th>
<th>2016</th>
<th>2017</th>
<th>2018</th>
<th>2019</th>
<th>2020¹</th>
<th>2021*</th>
</tr>
</thead>
<tbody>
<tr>
<td>IET Initiation - Total - Age 13-17</td>
<td>41.9%</td>
<td>42.8%</td>
<td>43.4%</td>
<td>41.6%</td>
<td>47.7%</td>
<td>47.7%</td>
</tr>
<tr>
<td>IET Initiation - Total - Age 18+</td>
<td>37.6%</td>
<td>37.8%</td>
<td>40.7%</td>
<td>42.1%</td>
<td>N/A</td>
<td>46.8%*</td>
</tr>
<tr>
<td>IET Initiation - Total - All Age</td>
<td>38.0%</td>
<td>38.0%</td>
<td>40.7%</td>
<td>42.1%</td>
<td>46.7%</td>
<td>46.7%</td>
</tr>
<tr>
<td>IET Engagement - Total - Age 13-17</td>
<td>15.0%</td>
<td>13.5%</td>
<td>15.2%</td>
<td>14.3%</td>
<td>20.3%</td>
<td>20.3%</td>
</tr>
<tr>
<td>IET Engagement - Total - Age 18+</td>
<td>9.9%</td>
<td>9.4%</td>
<td>11.9%</td>
<td>13.3%</td>
<td>N/A</td>
<td>18.5%*</td>
</tr>
<tr>
<td>IET Engagement - Total - All Age</td>
<td>10.2%</td>
<td>9.7%</td>
<td>12.3%</td>
<td>13.7%</td>
<td>18.1%</td>
<td>18.1%</td>
</tr>
</tbody>
</table>

Source: Prior year national Medicaid median

Reporting-only

2019 national Medicaid 75th percentile

*In 2021 CCOs must meet benchmark or improvement target for both Initiation and Engagement for ages 18+ to achieve measure.

2021 Improvement Targets: Minnesota method

Note on telehealth: This measure is telehealth eligible. For further information specific to Oregon, the Health Evidence Review Commission (HERC) has provided this [guideline](#) on telehealth services.

¹ Because of disruptions caused by the COVID-19 pandemic, the Metrics & Scoring Committee decided at its July 17, 2020, meeting to make all 2020 CCO incentive measures reporting only.
Measure changes in specifications from 2020 to MY2020/2021:

- Revised the Intake Period to end on November 14 of the measurement year.
- Clarified the Episode Date when detoxification occurs during an acute inpatient stay.
- Updated the step 3 instructions for ED and observation visits that result in an inpatient stay, to make them consistent with instructions in the Definitions section.
- Added value sets for opioid treatment services that are billed weekly or monthly to the denominator and numerators: OUD Monthly Office Based Treatment Visits Value Set, OUD Weekly Drug Treatment Service Value Set, OUD Weekly Non Drug Service Value Set.
- Updated the continuous enrollment period.
- HEDIS updated codes in MY2020/2021 Value Sets: Alcohol Abuse and Dependence Value Set, AOD Abuse and Dependence Value Set, Detoxification Value Set, IET Stand Alone Visits Value Set, IET POS Group 1 Value Set, Online Assessments Value Set, Opioid Abuse and Dependence Value Set, Other Drug Abuse and Dependence Value Set.

Member type: CCO A □  CCO B □  CCO G □

Specify claims used in the calculation:

<table>
<thead>
<tr>
<th></th>
<th>Only use claims from matching CCO that a member is enrolled with</th>
<th>Denied claims included</th>
</tr>
</thead>
<tbody>
<tr>
<td>Denominator event</td>
<td>Y</td>
<td>Y</td>
</tr>
<tr>
<td>Numerator event</td>
<td>N</td>
<td>Y</td>
</tr>
</tbody>
</table>

Measure Details

Definitions

<table>
<thead>
<tr>
<th>Term</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intake Period</td>
<td>January 1–November 13-14 of the measurement year. The Intake Period is used to capture new episodes of AOD abuse and dependence.</td>
</tr>
<tr>
<td>Index Episode</td>
<td>The earliest eligible encounter during the Intake Period with a diagnosis of AOD abuse or dependence. For ED or observation visits that result in an inpatient discharge, the Index Episode is the date of service.</td>
</tr>
<tr>
<td>Date of service for services billed weekly or monthly</td>
<td>For an opioid treatment service that bills monthly or weekly (OUD Weekly Non Drug Service Value Set; OUD Monthly Office Based Treatment Value Set; OUD Weekly Drug Treatment Service Value Set), if the service includes a range of dates, then use the earliest date as the date of service. Use this date for all relevant events (the IESD, negative diagnosis history and numerator events).</td>
</tr>
<tr>
<td>Index Episode Start Date (IESD)</td>
<td>Index Episode Start Date. The earliest date of service for an eligible encounter during the Intake Period with a diagnosis of AOD abuse or dependence. For an outpatient, intensive outpatient, partial hospitalization, observation, telehealth, detoxification or ED visit (not resulting in an inpatient stay), the IESD is the date of service.</td>
</tr>
</tbody>
</table>
For an inpatient stay or detoxification that occurred during an inpatient stay, the IESD is the date of discharge.

For detoxification (other than detoxification that occurred during an inpatient stay), the IESD is the date of service.

For an ED or observation visits that results in an inpatient stay, the IESD is the date of the inpatient discharge (an AOD diagnosis is not required for the inpatient stay; use the diagnosis from the ED or observation visit to determine the diagnosis cohort).

For direct transfers, the IESD is the discharge date from the last admission (an AOD diagnosis is not required for the transfer; use the diagnosis from the initial admission to determine the diagnosis cohort).

### Negative Diagnosis History

A period of 60 days (2 months) before the IESD when the member had no claims/encounters with a diagnosis of AOD abuse or dependence.

For an inpatient stay, use the admission date to determine the Negative Diagnosis History.

For ED or observation visits that result in an inpatient stay, use the earliest date of service (either the ED/observation date of service or the inpatient admission date) to determine the Negative Diagnosis History.

For direct transfers, use the first admission to determine the Negative Diagnosis History.

### Direct transfer

A direct transfer is when the discharge date from the first inpatient setting precedes the admission date to a second inpatient setting by one calendar day or less. For example:

- An inpatient discharge on June 1, followed by an admission to another inpatient setting on June 1, is a direct transfer.
- An inpatient discharge on June 1, followed by an admission to an inpatient setting on June 2, is a direct transfer.
- An inpatient discharge on June 1, followed by an admission to another inpatient setting on June 3, is not a direct transfer; these are two distinct inpatient stays.

Use the following method to identify admissions to and discharges from inpatient settings:

1. Identify all acute and nonacute inpatient stays (Inpatient Stay Value Set).
2. Identify the admission and discharge dates for the stay.

Data elements required denominator: Members 13 years and older as of December 31st of the measurement year who have medical, pharmacy and chemical dependency (inpatient and outpatient) benefits (i.e. CCO-A and CCO-B members) with a new episode of AOD abuse or dependence during the intake period (January 1 – November 13-14 of the measurement year). Note, members in hospice are excluded from the eligible population (see detail in HEDIS MY2020/2021 General Guideline 17).

Report two age stratifications and the total rate:
• 13–17 years
• 18+ years*
• Total

Report the following diagnosis cohorts for each age stratification and the total rate:

• Alcohol abuse or dependence
• Opioid abuse or dependence
• Other drug abuse or dependence
• Total*

*Note, only the adult 18 and above age group and its ‘total cohort’ rate is incentivized. In 2021 CCOs must meet benchmark or improvement target for both Initiation and Engagement for ages 18+ to achieve measure.

The new episode of AOD abuse or dependence during the intake period: Follow the steps below to identify the eligible population, which is the denominator for both rates

**Step 1** Identify the Index Episode. Identify all members in the specified age range who during the Intake Period had one of the following:

• An outpatient visit, telehealth, intensive outpatient visit or partial hospitalization with a diagnosis of AOD abuse or dependence. Any of the following code combinations meet criteria:
  – IET Stand Alone Visits Value Set with one of the following: Alcohol Abuse and Dependence Value Set, Opioid Abuse and Dependence Value Set, Other Drug Abuse and Dependence Value Set.
  – IET Visits Group 1 Value Set with IET POS Group 1 Value Set and with one of the following: Alcohol Abuse and Dependence Value Set, Opioid Abuse and Dependence Value Set, Other Drug Abuse and Dependence Value Set.
  – IET Visits Group 2 Value Set with IET POS Group 2 Value Set and with one of the following: Alcohol Abuse and Dependence Value Set, Opioid Abuse and Dependence Value Set, Other Drug Abuse and Dependence Value Set.
  – OUD Weekly Non Drug Service Value Set with Opioid Abuse and Dependence Value Set.
  – OUD Monthly Office Based Treatment Value Set with Opioid Abuse and Dependence Value Set.
  – OUD Weekly Drug Treatment Service Value Set with Opioid Abuse and Dependence Value Set.

• A detoxification visit (Detoxification Value Set) with one of the following: Alcohol Abuse and Dependence Value Set, Opioid Abuse and Dependence Value Set, Other Drug Abuse and Dependence Value Set.

• An ED visit (ED Value Set) with one of the following: Alcohol Abuse and Dependence Value Set, Opioid Abuse and Dependence Value Set, Other Drug Abuse and Dependence Value Set.
• An observation visit (Observation Value Set) with one of the following: Alcohol Abuse and Dependence Value Set, Opioid Abuse and Dependence Value Set, Other Drug Abuse and Dependence Value Set.

• An acute or nonacute inpatient discharge with one of the following: Alcohol Abuse and Dependence Value Set, Opioid Abuse and Dependence Value Set, Other Drug Abuse and Dependence Value Set. To identify acute and nonacute inpatient discharges:
  1. Identify all acute and nonacute inpatient stays (Inpatient Stay Value Set).
  2. Identify the discharge date for the stay.

• A telephone visit (Telephone Visits Value Set) with one of the following: Alcohol Abuse and Dependence Value Set, Opioid Abuse and Dependence Value Set, Other Drug Abuse and Dependence Value Set.

• An e-visit of virtual check-on (Online Assessments Value Set) with one of the following: Alcohol Abuse and Dependence Value Set, Opioid Abuse and Dependence Value Set, Other Drug Abuse and Dependence Value Set.

• An opioid treatment service (OUD Weekly Non Drug Service Value Set; OUD Monthly Office Based Treatment Value Set; OUD Weekly Drug Treatment Service Value Set) with a diagnosis of opioid abuse of dependence (Opioid Abuse and Dependence Value Set).

For members with more than one episode of AOD abuse or dependence, use the first episode.

For members whose first episode was an ED or observation visit that resulted in an inpatient stay, use the diagnosis from the ED or observation visit to determine the diagnosis cohort and use the inpatient discharge date as the IESD.

**Step 2** Select the Index Episode and stratify based on age and AOD diagnosis cohort.

• If the member has a claim with a diagnosis of alcohol abuse or dependence (Alcohol Abuse and Dependence Value Set), place the member in the alcohol cohort.

• If the member has a diagnosis of opioid abuse of dependence (Opioid Abuse and Dependence Value Set), place the member in the opioid cohort.

• If the member has a drug abuse or dependence that is neither for opioid or alcohol (Other Drug Abuse and Dependence Value Set), place the member in the other drug cohort.

If the member has multiple substance use diagnosis for the visit, report the member in all AOD diagnosis stratifications for which they meet criteria.

The total is not a sum of the diagnosis cohorts. Count members in the total denominator rate if they had at least one alcohol, opioid or other drug abuse or dependence diagnosis during the measurement period. Report member with multiple diagnoses on the Index Episode claim only once for the total rate for the denominator.
Step 3  Test for Negative Diagnosis History. Exclude members who had a claim/encounter with a diagnosis of AOD abuse or dependence (AOD Abuse and Dependence Value Set), AOD medication treatment (AOD Medication Treatment Value Set) or an alcohol or opioid dependency treatment medication dispensing event (Alcohol Use Disorder Treatment Medications List; Opioid Use Disorder Treatment Medications List) during the 60 days (2 months) before the IESD.

For an inpatient IESD, use the admission date to determine the 60-day Negative Diagnosis History period.

For an ED or observation visit that results in an inpatient stay, use the earliest date of service (either the ED/observation date of service or the inpatient admission date) to determine the Negative Diagnosis History period.

Step 4  Calculate continuous enrollment. Members must be continuously enrolled for 60 days (2 months) before the IESD through 48 47 days after the IESD (109 108 total days), with no gaps.

Required exclusions for denominator: Exclude members who use hospice services or elect to use a hospice benefit any time during the measurement year (using HEDIS MY2020/2021 Hospice Encounter Value Set and Hospice Intervention Value Set; see detail in HEDIS MY2020/2021 General Guideline 17). Exclude members who had a claim/encounter with a diagnosis of AOD abuse or dependence during the Negative Diagnosis History period (see detail in denominator section step 3).

Deviations from cited specifications for denominator: None.

Continuous enrollment criteria: Member must be continuously enrolled for 60 days (2 months) before the IESD through 48 47 days after the IESD (109 108 total days), with no gaps.

Allowable gaps in enrollment: None.

Anchor Date (if applicable): None.

Data elements required numerator:

Initiation of AOD Treatment within 14 days of the IESD

If the Index Episode was an inpatient discharge (or an ED/observation visit that resulted in an inpatient stay), the inpatient stay is considered initiation of treatment and the member is compliant.

If the Index Episode was an opioid treatment service that bills monthly (OUD Monthly Office Based Treatment Value Set), the opioid treatment service is considered initiation of treatment and the member is compliant.

If the Index Episode was not an inpatient discharge, the member must initiate treatment on the IESD or in the 13 days after the IESD (14 total days). Any of the following code combinations meet criteria for initiation:

- An acute or nonacute inpatient admission with a diagnosis (on the discharge claim) matching the IESD diagnosis cohort using one of the following: Alcohol Abuse and Dependence Value Set, Opioid Abuse
and Dependence Value Set, Other Drug Abuse and Dependence Value Set. To identify acute and nonacute inpatient admissions:

1. Identify all acute and nonacute inpatient stays (Inpatient Stay Value Set).
2. Identify the admission date for the stay.

- **IET Stand Alone Visits Value Set with** a diagnosis matching the IESD diagnosis cohort using one of the following: Alcohol Abuse and Dependence Value Set, Opioid Abuse and Dependence Value Set, Other Drug Abuse and Dependence Value Set.

- **Observation Value Set with** a diagnosis matching the IESD diagnosis cohort using one of the following: Alcohol Abuse and Dependence Value Set, Opioid Abuse and Dependence Value Set, Other Drug Abuse and Dependence Value Set.

- **IET Visits Group 1 Value Set with** IET POS Group 1 Value Set and a diagnosis matching the IESD diagnosis cohort using one of the following: Alcohol Abuse and Dependence Value Set, Opioid Abuse and Dependence Value Set, Other Drug Abuse and Dependence Value Set.

- **IET Visits Group 2 Value Set with** IET POS Group 2 Value Set and a diagnosis matching the IESD diagnosis cohort using one of the following: Alcohol Abuse and Dependence Value Set, Opioid Abuse and Dependence Value Set, Other Drug Abuse and Dependence Value Set.

- A telephone visit (Telephone Visit Value Set) with a diagnosis matching the IESD diagnosis cohort using one of the following: Alcohol Abuse and Dependence Value Set, Opioid Abuse and Dependence Value Set, Other Drug Abuse and Dependence Value Set.

- An e-visit or virtual check-in (Online Assessment Value) set with a diagnosis matching the IESD diagnosis cohort using one of the following: Alcohol Abuse and Dependence Value Set, Opioid Abuse and Dependence Value Set, Other Drug Abuse and Dependence Value Set.

- If the Index Episode was for a diagnosis of opioid abuse or dependence (Opioid Abuse and Dependence Value Set) an opioid treatment service (OUD Weekly Non Drug Service Value Set).

- If the Index Episode was for a diagnosis of opioid abuse or dependence (Opioid Abuse and Dependence Value Set) an opioid treatment service (OUD Monthly Office Based Treatment Value Set).

- If the Index Episode was for a diagnosis of alcohol abuse or dependence (Alcohol Abuse and Dependence Value Set) a medication treatment dispensing event (AOD Medication Treatment Value Set) or medication treatment during a visit (AOD Medication Treatment Value Set; OUD Weekly Drug Treatment Service Value Set).

- If the Index Episode was for a diagnosis of opioid abuse or dependence (Opioid Abuse and Dependence Value Set) a medication treatment dispensing event (Opioid Use Disorder Treatment Medications List) or medication treatment during a visit (AOD Medication Treatment Value Set; OUD Weekly Drug Treatment Service Value Set).

For all initiation events except medication treatment (AOD Medication Treatment Value Set; Alcohol Use Disorder Treatment Medications List; Opioid Use Disorder Treatment Medications List), initiation on the same day as the IESD must be with different providers in order to count.

*If a member is compliant for the Initiation numerator for any diagnosis cohort (i.e., alcohol, opioid, other drug) or for multiple cohorts, count the member only once in the Total Initiation numerator. The “Total” column is not the sum of the diagnosis columns.*
Exclude the member from the denominator for both indicators (Initiation of AOD Treatment and Engagement of AOD Treatment) if the initiation of treatment event is an inpatient stay with a discharge date after November 27 of the measurement year.

**Engagement of AOD Treatment**

**Step 1** Identify all members compliant for the Initiation of AOD Treatment numerator.

For members who initiated treatment via an inpatient admission, the 34-day period for engagement begins the day after discharge.

**Step 2** Identify members who had an opioid treatment service that bills monthly (OUD Monthly Office Based Treatment Value Set) or who had a visit that included medication administration (OUD Weekly Drug Treatment Service Value Set) beginning on the day after the initiation encounter through 34 days after the initiation event.

For these members, if the IESD Diagnosis cohort was a diagnosis of opioid abuse or dependence (Opioid Abuse and Dependence Value Set), the member is numerator compliant for Engagement of AOD Treatment.

**Step 3** Identify members whose initiation of AOD treatment was a medication treatment event (Alcohol Use Disorder Treatment Medications List; Opioid Use Disorder Treatment Medications List; AOD Medication Treatment Value Set).

These members are numerator compliant if they have two or more engagement events, where only one can be an engagement medication treatment event, beginning on the day after the initiation encounter through 34 days after the initiation event (total of 34 days).

**Step 4** Identify the remaining members whose initiation of AOD treatment was not a medication treatment event (members not identified in step 3).

The members are numerator compliant if they meet either of the following:

- At least one engagement medication treatment event.
- At least two engagement visits.

Two engagement visits can be on the same date of service but they must be with different providers in order to count as two events. An engagement visit on the same date of service as an engagement medication treatment event meets criteria (there is no requirement that they be with different providers).

Refer to the descriptions below to identify engagement visits and engagement medication treatment events.

Any of the following beginning on the day after the initiation encounter through 34 days after the initiation event (total of 34 days) meet criteria for an **engagement visit**:

- An acute or nonacute inpatient admission with a diagnosis (on the discharge claim) matching the IESD diagnosis cohort using one of the following: Alcohol Abuse and Dependence Value Set, Opioid Abuse
and Dependence Value Set, Other Drug Abuse and Dependence Value Set. To identify acute and nonacute inpatient admissions:

1. Identify all acute and nonacute inpatient stays (Inpatient Stay Value Set).
2. Identify the admission date for the stay.

- **IET Stand Alone Visits Value Set with** a diagnosis matching the IESD diagnosis cohort using one of the following: Alcohol Abuse and Dependence Value Set, Opioid Abuse and Dependence Value Set, Other Drug Abuse and Dependence Value Set.

- **Observation Value Set with** a diagnosis matching the IESD diagnosis cohort using one of the following: Alcohol Abuse and Dependence Value Set, Opioid Abuse and Dependence Value Set, Other Drug Abuse and Dependence Value Set.

- **IET Visits Group 1 Value Set with IET POS Group 1 Value Set and** a diagnosis matching the IESD diagnosis cohort using one of the following: Alcohol Abuse and Dependence Value Set, Opioid Abuse and Dependence Value Set, Other Drug Abuse and Dependence Value Set.

- **IET Visits Group 2 Value Set with IET POS Group 2 Value Set and** a diagnosis matching the IESD diagnosis cohort using one of the following: Alcohol Abuse and Dependence Value Set, Opioid Abuse and Dependence Value Set, Other Drug Abuse and Dependence Value Set.

- A telephone visit (Telephone Visit Value Set) **with** a diagnosis matching the IESD diagnosis cohort using one of the following: Alcohol Abuse and Dependence Value Set, Opioid Abuse and Dependence Value Set, Other Drug Abuse and Dependence Value Set.

- An e-visit or virtual check-in (Online Assessment Value) set with a diagnosis matching the IESD diagnosis cohort using one of the following: Alcohol Abuse and Dependence Value Set, Opioid Abuse and Dependence Value Set, Other Drug Abuse and Dependence Value Set.

- If the IESD Diagnosis cohort was a diagnosis of opioid abuse or dependence (Opioid Abuse and Dependence Value Set) an opioid treatment service (OUD Weekly Non Drug Service Value Set).

Either of the following meeting criteria for an engagement medication treatment event:

- If the IESD diagnosis was a diagnosis of alcohol abuse or dependence (Alcohol Abuse and Dependence Value Set), one or more medication treatment dispensing events (Alcohol Use Disorder Treatment Medications List) or medication treatment during a visit (AOD Medication Treatment Value Set), beginning on the day after the initiation encounter through 34 days after the initiation event (total of 34 days), meets criteria for Alcohol Abuse and Dependence Treatment.

- If the IESD diagnosis was a diagnosis of opioid abuse or dependence (Opioid Abuse and Dependence Value Set), one or more medication treatment dispensing events (Opioid Use Disorder Treatment Medications List) or medication treatment during a visit (AOD Medication Treatment Value Set), beginning on the day after the initiation encounter through 34 days after the initiation event (total of 34 days), meets criteria for Opioid Abuse and Dependence Treatment.

  *If the member is compliant for multiple cohorts,* only count the member once for the Total Engagement numerator. The Total Column is not the sum of the diagnosis columns.
Note: For members in the “other drug abuse or dependence” cohort, medication treatment does not meet numerator criteria for Initiation of AOD Treatment or Engagement of AOD Treatment.

Methadone is not included in the medication lists for this measure. Methadone for opioid use disorder is only administered or dispensed by federally certified opioid treatment programs and does not show up in pharmacy claims data. A pharmacy claim for methadone would be more indicative of treatment for pain than treatment for an opioid use disorder; therefore they are not included in the medication lists. The AOD Medication Treatment Value Set includes some codes that identify methadone treatment because these codes are used on medical claims, not pharmacy claims.

Required exclusions for numerator: None.

Deviations from cited specifications for numerator: None.

HEDIS Value Sets and Medication list related to the measure:

<table>
<thead>
<tr>
<th>Alcohol Abuse and Dependence Value Set</th>
</tr>
</thead>
<tbody>
<tr>
<td>ICD-10-CM Diagnosis</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>AOD Abuse and Dependence</th>
</tr>
</thead>
<tbody>
<tr>
<td>ICD-10-CM Diagnosis</td>
</tr>
</tbody>
</table>
### AOD Medication Treatment Value Set

<table>
<thead>
<tr>
<th>HCPCS</th>
</tr>
</thead>
<tbody>
<tr>
<td>H0020, H0033, J0570-J0575, J2315, Q9991, Q9992, S0109</td>
</tr>
</tbody>
</table>

### Detoxification Value Set

<table>
<thead>
<tr>
<th>HCPCS</th>
<th>ICD10PCS</th>
<th>UBREV</th>
</tr>
</thead>
<tbody>
<tr>
<td>H0008-H0014</td>
<td>HZ2ZZZZZ</td>
<td>0116, 0126, 0136, 0146, 0156</td>
</tr>
</tbody>
</table>

### ED Value Set

<table>
<thead>
<tr>
<th>CPT</th>
<th>UBREV</th>
</tr>
</thead>
<tbody>
<tr>
<td>99281-99285</td>
<td>0450-0452, 0456, 0459, 0981</td>
</tr>
</tbody>
</table>

### Hospice Encounter Value Set

<table>
<thead>
<tr>
<th>CPT/HCPCS</th>
<th>UBREV</th>
</tr>
</thead>
<tbody>
<tr>
<td>G9473-G9479, Q5003-Q5008, Q5010, S9126, T2042-T2046</td>
<td>0115, 0125, 0135, 0145, 0155, 0235, 0650-0652, 0655-0659</td>
</tr>
</tbody>
</table>

### Hospice Intervention Value Set

<table>
<thead>
<tr>
<th>CPT/HCPCS</th>
</tr>
</thead>
<tbody>
<tr>
<td>99377, 99378, G0182</td>
</tr>
</tbody>
</table>

### IET Stand Alone Visits Value Set

<table>
<thead>
<tr>
<th>CPT</th>
<th>HCPCS</th>
<th>UBREV</th>
</tr>
</thead>
</table>

### IET Visits Group 1 Value Set

<table>
<thead>
<tr>
<th>CPT</th>
<th>POS</th>
</tr>
</thead>
<tbody>
<tr>
<td>90791, 90792, 90832-90834, 90836-90840, 90845, 90847, 90849, 90853, 90875, 90876</td>
<td>02, 03, 05, 07, 09, 11-20, 22, 33, 49, 50, 52, 53, 57, 58, 71, 72</td>
</tr>
</tbody>
</table>

### IET Visits Group 2 Value Set

<table>
<thead>
<tr>
<th>CPT</th>
<th>POS</th>
</tr>
</thead>
<tbody>
<tr>
<td>99221-99223, 99231-99233, 99238, 99239, 99251-99255</td>
<td>02, 52, 53</td>
</tr>
</tbody>
</table>
### Inpatient Stay Value Set

<table>
<thead>
<tr>
<th>UBREV</th>
</tr>
</thead>
</table>

### Observation Value Set

<table>
<thead>
<tr>
<th>CPT</th>
</tr>
</thead>
<tbody>
<tr>
<td>99217-99220</td>
</tr>
</tbody>
</table>

### Online Assessments Value Set

<table>
<thead>
<tr>
<th>CPT</th>
</tr>
</thead>
<tbody>
<tr>
<td>98969-98972, 99421-99423, 99444, 99457, G0071, G2010, G2012, G2061-G2063</td>
</tr>
</tbody>
</table>

### Opioid Abuse and Dependence Value Set

<table>
<thead>
<tr>
<th>ICD-10-CM Diagnosis</th>
</tr>
</thead>
</table>

### Other Drug Abuse and Dependence Value Set

<table>
<thead>
<tr>
<th>ICD-10-CM Diagnosis</th>
</tr>
</thead>
</table>
Telephone Visits Value Set

CPT
98966, 98967, 98968, 99441, 99442, 99443

OUD Monthly Office Based Treatment Visits Value Set

HCPCS
G2086, G2087

OUD Weekly Drug Treatment Service Value Set

HCPCS
G2067-G2070, G2072, G2073

OUD Weekly Non Drug Service Value Set

HCPCS
G2071, G2074-G2077, G2080

Alcohol Use Disorder Treatment Medications

<table>
<thead>
<tr>
<th>Description</th>
<th>Prescription</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aldehyde dehydrogenase inhibitor</td>
<td>• Disulfiram (oral)</td>
</tr>
<tr>
<td>Antagonist</td>
<td>• Naltrexone (oral and injectable)</td>
</tr>
<tr>
<td>Other</td>
<td>• Acamprosate (oral; delayed-release tablet)</td>
</tr>
</tbody>
</table>

Opioid Use Disorder Treatment Medications

<table>
<thead>
<tr>
<th>Description</th>
<th>Prescription</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antagonist</td>
<td>• Naltrexone (oral and injectable)</td>
</tr>
<tr>
<td>Partial agonist</td>
<td>• Buprenorphine (sublingual tablet, injection, implant)</td>
</tr>
<tr>
<td></td>
<td>• Buprenorphine/naloxone (sublingual tablet, buccal film, sublingual film)</td>
</tr>
</tbody>
</table>

Note HEDIS NDC lists for the medications are available at: https://www.ncqa.org/hedis/measures/